Patents by Inventor Janine Bilsborough

Janine Bilsborough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
    Publication number: 20210093718
    Abstract: Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohn's Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.
    Type: Application
    Filed: November 23, 2020
    Publication date: April 1, 2021
    Inventors: Janine Bilsborough, Stephan R. Targan, Bradley Henkle
  • MITIGATION AND REVERSAL OF FIBROSIS AND INFLAMMATION BY INHIBITION OF TL1A FUNCTION AND RELATED SIGNALING PATHWAYS
    Publication number: 20200190203
    Abstract: The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 18, 2020
    Inventors: David Q. Shih, Stephan R. Targan, Dalin Li, Janine Bilsborough
  • Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway
    Patent number: 10633449
    Abstract: The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: April 28, 2020
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: David Q. Shih, Stephan R. Targan, Dalin Li, Janine Bilsborough
  • METHODS OF DIAGNOSING INFLAMMATORY BOWEL DISEASE THROUGH RNASET2
    Publication number: 20190300957
    Abstract: The present invention describes methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNA-SET2, TL1A and/or IFN-?. The invention further provides a process for patient identification and/or stratification.
    Type: Application
    Filed: March 17, 2017
    Publication date: October 3, 2019
    Inventors: Rebecca GONSKY, Stephan R. TARGAN, Richard L. DEEM, Philip FLESHNER, Dermot P. MCGOVERN, Janine BILSBOROUGH
  • NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
    Publication number: 20190247498
    Abstract: Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohn's Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.
    Type: Application
    Filed: April 15, 2019
    Publication date: August 15, 2019
    Inventors: Janine Bilsborough, Stephan R. Targan, Bradley Henkle
  • Neutralizing anti-TL1A monoclonal antibodies
    Patent number: 10322174
    Abstract: Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohn's Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 18, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: Janine Bilsborough, Stephan Targan, Bradley Henkle
  • Methods of treating atopic dermatitis with IL-31 monoclonal antibodies
    Patent number: 10259868
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: April 16, 2019
    Assignee: ZYMOGENETICS, INC.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • MODELS, METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY BOWEL DISEASE
    Publication number: 20180156781
    Abstract: The invention provides models of various conditions including but not limited to intestinal inflammation and/or fibrosis, inflammatory bowel disease, colitis, acute colitis, and chronic colitis, and methods of using such models for designing, screening and developing therapeutics for those conditions. The invention also provides methods, compositions, and kits for treating those conditions.
    Type: Application
    Filed: May 12, 2016
    Publication date: June 7, 2018
    Inventors: David Q. SHIH, Stephan R. TARGAN, Yoshitake KANAZAWA, Janine BILSBOROUGH
  • NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
    Publication number: 20180110855
    Abstract: Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohn's Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.
    Type: Application
    Filed: October 24, 2017
    Publication date: April 26, 2018
    Inventors: Janine Bilsborough, Stephan Targan, Bradley Henkle
  • METHODS OF TREATING INFLAMMATORY BOWEL DISEASE WITH IFN-GAMMA THERAPY
    Publication number: 20180051078
    Abstract: The present invention describes methods for treating inflammatory disorders of the gastrointestinal tract, including but not limited to Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC) and/or medically refractory ulcerative colitis (MR-UC) using anti-IFNG therapy. The present invention also describes a process for patient risk stratification.
    Type: Application
    Filed: March 15, 2016
    Publication date: February 22, 2018
    Applicant: Cedars-Sinai Medical Center
    Inventors: Stephan R. TARGAN, Janine BILSBOROUGH, Dermot P. MCGOVERN
  • Use of IL-31 monoclonal antibodies for treating neuronal inflammation
    Patent number: 9834602
    Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: December 5, 2017
    Assignee: ZYMOGENETICS INC.
    Inventors: Yue Yao, Janine Bilsborough
  • Use of IL-31RA monoclonal antibodies for treating neuronal inflammation
    Patent number: 9828431
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: November 28, 2017
    Assignee: ZYMOGENETICS, INC.
    Inventors: Yue Yao, Janine Bilsborough
  • METHODS OF TREATING ATOPIC DERMATITIS WITH IL-31 MONOCLONAL ANTIBODIES
    Publication number: 20170260267
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Application
    Filed: May 17, 2017
    Publication date: September 14, 2017
    Inventors: ANTHONY W. SIADAK, JANINE BILSBOROUGH, SHIRLEY RENE
  • USE OF IL-31RA MONOCLONAL ANTIBODIES FOR TREATING NEURONAL INFLAMMATION
    Publication number: 20170190780
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Application
    Filed: March 16, 2017
    Publication date: July 6, 2017
    Inventors: Yue Yao, Janine Bilsborough
  • USE OF IL-31 MONOCLONAL ANTIBODIES FOR TREATING NEURONAL INFLAMMATION
    Publication number: 20170190771
    Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Application
    Filed: March 15, 2017
    Publication date: July 6, 2017
    Inventors: Yue Yao, Janine Bilsborough
  • Method of treating atopic dermatitis with IL-31 monoclonal antibodies
    Patent number: 9683037
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: June 20, 2017
    Assignee: ZYMOGENETICS INC
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Use of an IL-31 monoclonal antibody for antagonizing signal transduction in spinal cord cells
    Patent number: 9631021
    Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: April 25, 2017
    Assignee: ZYMOGENETICS INC.
    Inventors: Yue Yao, Janine Bilsborough
  • Method treating neuronal tissue inflammation using an IL-31RA monoclonal antibody
    Patent number: 9631022
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: April 25, 2017
    Assignee: ZYMOGENETICS INC.
    Inventors: Yue Yao, Janine Bilsborough
  • USE OF IL-31 MONOCLONAL ANTIBODIES FOR TREATING ATOPIC DERMATITIS
    Publication number: 20170044253
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Application
    Filed: November 1, 2016
    Publication date: February 16, 2017
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • IL-31 monoclonal antibodies
    Patent number: 9512219
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: December 6, 2016
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene